MarketAnalysisMarketAnalysis
NASDAQ:BNTX

BioNTech SE - NASDAQ:BNTX - Comprehensive analysis

Free evaluation through quantitative algorithms BioNTech SE - NASDAQ:BNTX

Quant Rating

1

Strong Sell

2

Sell

3

Hold

4

Buy

5

Strong Buy


The overall quant rating is not an average of the factor grades listed.Instead, it gives greater weight to the metrics with the strongest predictive value.

Growth-Scoring Model Detail

Name

Fatcor
Percentage

Total Revenue Growth Over Prior Year

-27.96

Market

2

Sector

8

Gross Profit Growth Over Prior Year

-31.36

Market

2

Sector

5

EBITDA Growth Over Prior Year

0

Market

0

Sector

0

EBITA Growth Over Prior Year

0

Market

0

Sector

0

EBIT Growth Over Prior Year

0

Market

0

Sector

0

Earnings from Cont. Ops. Growth Over Prior Year

0

Market

0

Sector

0

Net Income Growth Over Prior Year

0

Market

0

Sector

0

Normalized Net Income Growth Over Prior Year

0

Market

0

Sector

0

Diluted EPS before Extra Growth Over Prior Year

0

Market

0

Sector

0

A/R Growth Over Prior Year

-31.78

Market

3

Sector

8

Inventory Growth Over Prior Year

-20.8

Market

5

Sector

8

PPE Net Growth Over Prior Year

21.8

Market

92

Sector

84

Total Assets Growth Over Prior Year

-2.07

Market

25

Sector

44

Tangible Book Value Growth Over Prior Year

-4.39

Market

18

Sector

49

Common Equity Growth Over Prior Year

-4.12

Market

21

Sector

50

Cash from Ops. Growth Over Prior Year

-96.13

Market

1

Sector

2

CAPEX Growth Over Prior Year

14.55

Market

73

Sector

74

Dividend per Share Growth Over Prior Year

0

Market

36

Sector

48

Levered Free Cash Flow Growth Over Prior Year

-87.07

Market

1

Sector

5

Unlevered Free Cash Flow Growth Over Prior Year

-86.9

Market

2

Sector

4

Profitability-Scoring Model Detail

Name

Fatcor
Percentage

Gross Margin %

81

Market

93

Sector

82

SG&A Margin %

21.8

Market

69

Sector

35

EBITDA Margin %

-37.55

Market

1

Sector

17

EBITA Margin %

-44.73

Market

1

Sector

17

EBIT Margin %

-46.73

Market

1

Sector

17

Earnings from Cont. Ops Margin %

-24.18

Market

2

Sector

25

Net Income Margin %

-24.18

Market

2

Sector

26

Net Income Avail. for Common Margin %

-24.18

Market

2

Sector

25

Normalized Net Income Margin %

-12.81

Market

1

Sector

26

Levered Free Cash Flow Margin %

19.45

Market

76

Sector

91

Unlevered Free Cash Flow Margin %

19.73

Market

73

Sector

91

Return on Assets %

-3.53

Market

1

Sector

63

Return on Capital %

-4

Market

1

Sector

63

Return on Equity %

-3.36

Market

3

Sector

72

Return on Common Equity %

-3.36

Market

3

Sector

72

Total Asset Turnover

0.12

Market

10

Sector

38

Sub-Scoring Model

Valuation
Momentum
Growth
Profitability
80
60
40
20
Valuation: 79
Momentum: 63
Growth: 22
Profitability: 21

Valuation-Scoring Model Detail

Name

Fatcor
Percentage

TEV/LTM Total Revenue

3.03

Market

42

Sector

50

TEV/LTM EBITDA

0

Market

0

Sector

0

P/LTM Normalized EPS

0

Market

0

Sector

0

P/BV

1.25

Market

10

Sector

34

TEV/LTM Unlevered FCF

15.58

Market

18

Sector

43

Momentum-Scoring Model Detail

Name

Fatcor
Percentage

1M Price Performance

15.64

Market

99

Sector

72

3M Price Performance

7.06

Market

71

Sector

70

6M Price Performance

-8.86

Market

36

Sector

65

9M Price Performance

7.27

Market

62

Sector

76

1Y Price Performance

7.78

Market

49

Sector

75

Start analyzing BioNTech SE - NASDAQ:BNTX with easy-to-understand research reports

Start analyzing Recent popular companies with easy-to-understand research reports